老年人接种JN.1适配mRNA疫苗后中和抗体应答稳健但细胞免疫异质
研究纳入62名老年人(中位年龄63.5岁,41人接种Comirnaty、21人接种Spikevax),在接种JN.1 mRNA疫苗前和接种后一个月检测中和抗体、T细胞应答及S2特异性抗体。两种疫苗均显著增强针对野生型、JN.1及多个亚谱系的中和抗体,S2靶向抗体也显著升高,约半数参与者诱导出IFNγ+CD8+或CD4+ T细胞。结论认为JN.1单价mRNA疫苗在老年人中引发广谱交叉中和及S2定向体液免疫,但细胞应答仍呈异质性。
要点
- JN.1 mRNA疫苗显著增强老年人针对野生型、JN.1及多个亚谱系的中和抗体。
- S2靶向抗体显著升高,提示识别保守刺突区域。
- 约半数参与者诱导IFNγ+CD8+或CD4+ T细胞,细胞免疫应答异质。
核心结论
- JN.1单价mRNA疫苗在老年人中引发广谱交叉中和及S2定向体液免疫,但细胞应答呈异质性。
研究设计与样本
- 队列研究纳入62名参与者(中位年龄63.5岁;41名Comirnaty接种者、21名Spikevax接种者),在JN.1 mRNA疫苗接种前和接种后一个月进行评估。
- 中和抗体滴度采用替代病毒中和试验(sVNT)或蚀斑减少中和试验(PRNT)评估。
- T细胞应答通过细胞内细胞因子染色分析,S2特异性抗体水平通过ELISA定量。
主要发现
- 两种JN.1疫苗均显著增强针对野生型、JN.1及多个亚谱系的中和抗体。
- S2靶向抗体也显著增加,表明识别保守刺突区域。
- 约半数参与者显示诱导出IFNγ+CD8+或CD4+ T细胞。
临床怎么用
- JN.1适配mRNA疫苗可用于增强老年人对包括KP.2、KP.3、XEC、XDV、LP.8.1和NB.1.8.1在内的新兴变异株的交叉中和体液免疫。
- 需关注老年人接种后细胞免疫应答的异质性,继续监测并考虑在下一代疫苗设计中纳入保守T细胞表位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rapid evolution of SARS-CoV-2 continues to challenge vaccine effectiveness, particularly in elderly individuals at higher risk of severe disease. The World Health Organization has recommended the use of a monovalent JN.1 lineage vaccine antigen for updated COVID-19 vaccines since April 2024. It remains crucial to determine whether these JN.1-adapted vaccines induce cross-protective immunity against emerging variants, including KP.2, KP.3, XEC, XDV, LP.8.1, and NB.1.8.1. METHODS: A cohort of 62 participants (median age 63.5 years; 41 Comirnaty and 21 Spikevax recipients) was studied before and one month after JN.1 mRNA vaccination. Neutralizing antibody titres were assessed by surrogate virus neutralization test (sVNT) or plaque-reduction neutralization test (PRNT). T cell responses were analyzed by intracellular cytokine staining, and S2-specific antibody levels were quantified by ELISA. RESULTS: Both JN.1 vaccines markedly enhanced neutralizing antibodies against wild-type, JN.1, and multiple sublineages. S2-targeting antibodies also increased significantly, indicating recognition of conserved spike regions. Approximately half of the participants showed induction of IFNγ+CD8+ or CD4+ T cells. CONCLUSIONS: The monovalent JN.1 mRNA vaccines elicit broad cross-neutralizing and S2-directed humoral immunity in the elderly, though cellular responses remain heterogeneous. Continued monitoring and inclusion of conserved T cell epitopes in next-generation vaccine designs are warranted to sustain protection against future variants.
引用
- Tang YS, Chen C, Lv H, et al. Robust cross-neutralizing antibody responses but variable cellular immunity following either Comirnaty and Spikevax JN.1-adapted mRNA vaccination in the elderly. Vaccine. 2026. PMID: 42060980. doi:10.1016/j.vaccine.2026.128634
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。